Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Cash & Equivalents: 2011-2025

Historic Cash & Equivalents for Mimedx Group (MDXG) over the last 14 years, with Sep 2025 value amounting to $142.1 million.

  • Mimedx Group's Cash & Equivalents rose 60.00% to $142.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.1 million, marking a year-over-year increase of 60.00%. This contributed to the annual value of $104.4 million for FY2024, which is 27.34% up from last year.
  • Per Mimedx Group's latest filing, its Cash & Equivalents stood at $142.1 million for Q3 2025, which was up 19.53% from $118.9 million recorded in Q2 2025.
  • In the past 5 years, Mimedx Group's Cash & Equivalents registered a high of $142.1 million during Q3 2025, and its lowest value of $48.5 million during Q1 2024.
  • For the 3-year period, Mimedx Group's Cash & Equivalents averaged around $89.0 million, with its median value being $85.4 million (2023).
  • Per our database at Business Quant, Mimedx Group's Cash & Equivalents dropped by 24.27% in 2022 and then surged by 119.50% in 2025.
  • Mimedx Group's Cash & Equivalents (Quarterly) stood at $87.1 million in 2021, then dropped by 24.27% to $66.0 million in 2022, then grew by 24.34% to $82.0 million in 2023, then rose by 27.34% to $104.4 million in 2024, then spiked by 60.00% to $142.1 million in 2025.
  • Its last three reported values are $142.1 million in Q3 2025, $118.9 million for Q2 2025, and $106.4 million during Q1 2025.